|
Annual Plan 2006-07 Objective Outcome Output [Physical Deliverable] 5 6 140 bedded Trauma To provide secondary health care services to the Centre to be patient with 500 beds to the residents of West commissioned. Delhi. To complete construction To provide Super Speciality Health Care Service work by September 2006. with 300 beds. Const. Work of 500 new To provide tertiary health care servicesto the ward block to be started. residents of Trans Yamuna Area and also imparting education to undergraduate and post graduate medicinal students. To complete 75% To provide super speciality construction work of the services with 650 beds. Hospital Building i.To meet establishment To provide expenditure. prisoners. ii.To purchase medicines machinery and equipment. health care medical care.
Burdett, D., "The Internet Open Trading Protocol", RFC 2801, April 2000. K. Matsuyama and K. Fujimura, "Distributed Digital-Ticket Management for Rights Trading System", 1st ACM Conferences on Electronic Commerce, November 1999. M. Terada, H. Kuno, M. Hanadate, and K. Fujimura, "Copy Prevention Scheme for Rights Trading Infrastructure", 4th Smart Card Research and Advanced Application Conference CARDIS 2000 ; , September 2000. "Extensible Mark Up Language XML ; 1.0 Second Edition ; ", A W3C Recommendation, : w3 TR REC-xml , October 2000.
There were significant effects for the delay length [F 2, 30 ; 16.92; p 0.001] and the drug delay interaction [F 2, 30 ; 4.14; p 0.026]. When error rates were adjusted for the performance in the.
The authors conclude that this study, which was powered to show a 25% survival advantage with high-dose melphalan as compared with melphalan plus dexamethasone, did not show any superiority of high-dose melphalan over melphalan plus dexamethasone.
Buy cheap Melphalan online
Out the duration of treatment that paralleled and preceded the similar progressive decline in ANC. The number of CFU-GM femur decreased from 26, 500 on day 1 to 300 on the last day of treatment 0.7% of baseline ; . In animals that had survived 28 days of melphalan treatment, CFU-GM content recovered 10fold within 1 week of completing treatment, reaching nearly 3, 000 CFU-GM femur 9.5% of baseline ; . In acetyldinaline-treated animals, the CFU-GM compartment was not severely affected by the treatment Fig. 3B ; . The steep decline seen with melphalan treatment was not seen in the CFU-GM compartment in these animals. Femoral content of CFU-GM was reduced 50% by the 10th day of acetyldinaline treatment, yet remained at 50% for the duration of therapy. Recovery of CFU-GM content was complete within 7 days of the end of treatment 110% of baseline ; . The CFU-GM compartment in the gemcitabine-treated animals was not as severely affected as it had been by melphalan Fig. 3C ; . Femoral CFU-GM content reached nadir on day 4, at 40% of baseline. This nadir level correlated with the nadir level in ANC. The progressive decline in CFU-GM content observed previously with melphalan was not apparent in the gemcitabinetreated animals. After the day-4 nadir, the CFU-GM content recovered slightly, to 52% of baseline by day 28. One week after discontinuing gemcitabine, the CFU-GM compartment had recovered completely, similar to the postacetyldinaline period. Therefore, the effects of gemcitabine on the CFU-GM compartment were qualitatively similar in all respects to that of CI994 but markedly different from that of melphalan. The levels of CFU-GMs in vehicle-treated animals remained stable throughout the trial except for a decrease 24 h into treatment. This dip may have been the result of mobilization of progenitors in response to stress or injected volume. Femoral CFU-GM content was 20, 000 40, 000 and averaged 36, 000 in the vehicle arm Fig. 3D ; . Melphalan, acetyldinaline, and gemcitabine treatment caused a significant decrease in CFU-Meg content on day 4 of treatment to 56, 25, and 27% of baseline, respectively Fig. 4 ; . From this time point, the melphalan-treated animals showed a.
AGITATED BEHAVIOR PSYCHIATRIC DISORDERS STATEWIDE ALS PROTOCOL CRITERIA: A. Patient with a psychiatric or behavioral disorder who is at imminent risk of self-injury or is a threat to others. OR B. Patient with a medical condition causing agitation and possibly violent behavior. Examples of these conditions are: 1. Alcohol or drug e.g. PCP, methamphetamine, cocaine ; intoxications 2. Hypoglycemia 3. Stroke 4. Drug overdose 5. Post-ictal after seizure 6. Head trauma Procedure for patients that require physical restraint: A. All Patients: 1. Use the minimum amount of restraint necessary to safely accomplish patient care and transportation with regard to the patient's dignity. 2. Assure that adequate personnel are present and that police assistance has arrived, if available, before attempts to restrain patient. 3. Restrain all 4 extremities with patient supine on stretcher.5, 6, 7, 8 Use soft restraints to prevent the patient from injuring him or herself or others.9 a. If the handcuffs or law enforcement devices are used to restrain the patient, a law enforcement officer should accompany the patient in the ambulance b. It is preferable that a law enforcement officer follows the ambulance in a patrol car to the receiving facility if physical restraint is necessary. 5. Do not place restraints in a manner that may interfere with evaluation and treatment of the patient or in any way that may compromise patient's respiratory effort.10 6. If the patient is spitting, may cover his her face with a surgical mask or with a NRB mask with high flow oxygen.11 7. Evaluate circulation to the extremities frequently. 8. Thoroughly document reasons for restraining the patient, the restraint method used, and results of frequent reassessment. Possible Medical Command Orders: A. Additional benzodiazepine Notes: 1. Verbal techniques include: a. Direct empathetic and calm voice. b. Present clear limits and options. c. Respect personal space. d. Avoid direct eye contact. e. Non-confrontational posture. 2. Do not permit patient to continue to struggle against restraints. This can lead to death due to severe rhabdomyolysis, acidosis, dysrhythmia, or respiratory failure. Medical command should be contacted for possible chemical restraint with sedative medication. 3. If age 65, reduce doses of sedative benzodiazepines in half. 4. Regional or service policy may permit intranasal midazolam, but this may not be as effective as parenteral medications. 5. Initial "take down" may be done in a prone position to decrease the patient's visual field and ability to bite, punch, and kick. After the individual is controlled, he she should be restrained to the stretcher or other transport device in the supine position. 6. DO NOT restrain patient in a hog-tied or prone position. 7. DO NOT sandwich patient between devices, such as long boards or Reeve's stretchers, for transport. Avoid restraint to unpadded devices like backboards. 8. A stretcher strap that fits snuggly just above the knees is effective in decreasing the patient's ability to kick. Effective 7 1 07 Page 8001-2 of 4 and memantine.
Bolic steroids in the treatment of acquired aplastic anemia. Blood 34: 283, 1969. Gordon Smith, E. C., Ahuja, S., and Lewis, S. M.: Oxymetholone treatment in aplastic anemia. Brit. J. Haemat. 20: 670.
GVHD prophylaxis: Ciclosporin: 5mg kg day i.v. days 1 to + then continue with 3mg kg i.v. Switch to oral ciclosporin once engraftment has occurred and the patient is tolerating oral intake. Methotrexate MTX ; : 15mg m2 i.v. bolus on days + 1 then MTX 10mg m2 i.v. bolus on days: + 3, + 6, + 11. 21 APPENDIX 7 - INTERMEDIATE DOSE INTRAVENOUS MELPHALAN TREATMENT REGIMEN USED IN AMYLOIDOSIS Melphalan 25 mg m2 i.v. infusion in 100 ml saline over 30 mins, day 1 Dexamethasone 20 mg po once daily can be omitted ; , days 1-4 The first dose of melphalan should be given as an inpatient with observation for the next 2448 hours. Dexamethasone should be omitted in patients at risk of fluid overload particularly patients with cardiac and or nephrotic syndrome. Chemotherapy is repeated every 28 days providing neutrophils are 1.0 x 109 l and platelets are 80 x 109 l. Patients who have their chemotherapy delayed may receive G-CSF support from day 5 of their next course for a total of 7 days, at the discretion of the physician. Patients who still have treatment delay of greater than 14 days should receive dexamethasone 20 mg po days 1-4 weekly until counts recover and meperidine.
Flammatory effect as confirmed by paw swelling and, therefore, this dose of carrageenan was used in the next step of the experiment. The effect of the age of rats on the sensory and inflammatory response was also evaluated. The obtained results indicate that rats 26 months old have similar sensitivity to mechanical stimuli and inflammatory reaction which agrees with the results obtained by other authors [Hylden et al., Pain, 1989; Torsney et al., J Neurophysiol, 2002]. At the following stage of the experiment, the analyzed model was applied to determine the effects of morphine and indomethacin as model substances on the change in sensory and inflammatory reaction in the carrageenan test. Based on our von Frey's test results and swelling size 3 h and 6 h after carrageenan injection, it was revealed that both morphine 5 mg kg sc ; and indomethacin 10 mg kg sc ; induced analgesic effect and reduced swelling, with indomethacin effect being more potent and longerlasting up to 6 both tests. It is noteworthy that a centrally acting opioid, morphine, also produces peripheral action which confirms its peripheral anti-inflammatory activity as reported earlier by other authors [Honore et al., Pain, 1997]. Concluding, automated von Frey's method may be used for evaluation of sensory perception changes in inflammation.
Percent of melphalan and completed additional training office at needs and mephenytoin.
63 Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763. Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitorcell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824. Carella AM, Champlin R, Slavin S et al. Mini-allografts: ongoing trials in humans. Bone Marrow Transplant 2000; 25: 345-350. Childs R, Clave E, Contentin N et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999; 94: 3234-3241. Molina AJ, Sandmaier BM, Storb R. Nonmyeloablative hematopoietic stem cell allografting. Curr Opin Organ Transplant 2000; 5: 366-371. Giralt S, Thall PF, Khouri I et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631-637. Spitzer TR. Nonmyeloablative allogeneic stem cell transplant strategies and the role of mixed chimerism. The Oncologist 2000; 5: 215-223. Gleit ZL, Cameron AM, Fuchimoto Y et al. Persistent chimerism despite antidonor MHC in vitro responses in miniature swine following allogeneic hematopoietic cell transplantation. Transplantation 2002; 74: 1260-1266. Huang CA, Fuchimoto Y, Scheier-Dolberg R et al. Stable mixed chimerism and tolerance using a nonmyeloablative preparative regimen in a large-animal model. J Clin Invest 2000; 105: 173-181. Kawai T, Cosimi AB, Colvin RB et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 1995; 59: 256-262. Spitzer TR, Delmonico F, Tolkoff-Rubin N et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999; 68: 480-484. Butcher JA, Hariharan S, Adams MB et al. Renal transplantation for end-stage renal disease following bone marrow transplantation: a report of six cases, with and without immunosuppression. Clin Transplant 1999; 13: 330-335. Remuzzi G. Cellular basis of long-term organ transplant acceptance: pivotal role of intrathymic clonal deletion and thymic dependence of bone marrow microchimerism-associated tolerance. J Kidney Dis 1998; 31: 197-212. Stewart FM, Crittenden RB, Lowry PA et al. Long-term engraftment of normal and post-5-fluorouracil murine marrow into normal nonmyeloablated mice. Blood 1993; 81: 2566-2571.
Well, moving on to lenalidomide there were several reports, one on lenalidomide plus dexamethasone, and at least two trials with lenalidomide with melphalan and prednisone and then Dr. Antonio Palumbo updated his data that he previously reported at ASCO. Can we have you discuss the lenalidomide therapies please? The first study was actually developed at Mayo and is a phase 2 study reported by Dr. Martha Lacy at this ASH meeting in which the PR rate overall response rate was an unprecedented 91% and the CR rate was at a very high 18%. Patients who actually continued on therapy with Revlimid dex uninterrupted by transplant had a combined CR VGPR in the first 4 months of therapy of 56% and when the therapy was continued in another cohort of patients, about half the patients continued on Revlimid and dexamethasone uninterrupted by transplantation either by their own choice or physician choice. In that group of patients the CR plus VGPR rate was 67%. These rates are as high, or higher, than can be achieved with transplant even double transplant. Now we are beginning to see efficacy that is quite high. The question is how durable are these responses and of course this was only a 2-year experience as opposed to the transplant experiences which are much longer. It is very promising that in 2 years the overall survival in this group of patients is 90%. This regimen, which is very well tolerated and is an oral regimen as opposed to the Velcade regimen, achieves at least comparable if not better response rates and they appear to be durable; time will tell. The second trial that was a follow-up of this trial we brought to the Eastern Cooperative Oncology Group and compared Revlimid dex in the standard doses of dexamethasone as Day 1 through 4, 9 through 12, and 17 through 21 in a 28-day cycle. After 4 cycles, the patients were reduced to Day 1 through 4, dexamethasone. The important part about this trial, however, was that there was a low-dose dexamethasone arm in which patients received only 40 mg of dexamethasone weekly. Just one day a week Day 1, 8, 15, and 22. The question here was could the low-dose dexamethasone avoid some of the toxicities that were being seen with the high-dose dexamethasone? The data monitoring committee has not yet released the response data from this trial; however, this is presented primarily because of the and meprobamate.
1. Bierman PJ, Vose JM, Armitage JO. Autologous transplantation for Hodgkin's disease: Coming of age? Blood 1994; 83: 1161-4. Yuen AR, Rosenberg SA, Hoppe RTet al. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997; 89: 814-22. Horning SJ, Chao NJ, Negrin RS et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices. Blood 1997; 89: 801-13. Linch DC, Winefield D, Goldstone AH et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomized trial. Lancet 1993; 341: 1051- . 5. O'Brien MER, Milan S, Cunningham D et al. High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease - a pragmatic prognostic index. Br J Cancer 1996; 73: 1272-7. Burns LJ, Daniels KA, McGlave PB et al. Autologous stem cell transplantation for refractory and relapsed Hodgkin's disease: Factors predictive of prolonged survival. Bone Marrow Transplant 1995; 16: 13-8. Nademanee A, O'Donnell MR, Snyder DS et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: Results in 85 patients with analysis of prognostic factors. Blood 1995; 85: 1381-90. Reece D. Early autologous bone marrow transplantation ABMT ; in the treatment of Hodgkin's disease. Leuk Lymph 1995; 15 Suppl 1 ; : 55-7. 9. Jagannath S, Armitage JO, Dicke KA et al. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1989; 7: 179-85. Chopra R, McMillan AK, Linch DC et al. The place of high-dose beam therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 1993; 81: 1137 Phillips GL, Wolff SN, Herzig RH et al. Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy aml autologous bone marrow transplantation. Blood 1989; 73: 2086 Rapoport AP, Rowe JM, Kouides PA et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: Value of pretransplant disease status for predicting outcome. J Clin Oncol 1993; 11: 2351-61. Gmur J, Burger J, Schanz U et al. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet 1991; 388: 1223-6. Stahel RA, Jost LM, Cerny T et al. Randomized study of recombinant human granulocyte colony-stimulating factor after 15. 16. high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol 1994; 12: 1931-8. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Stat Assoc 1958; 63: 457-81. Yahalom J, Gulati SC, Toia M et al. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease. J Clin Oncol 1993; 11: 1062-70. Ager S, Wimperis JZ, Tolliday B et al. Autologous bone marrow transplantation for Hodgkin's disease - afive-yearsingle centre experience. Leuk Lymph 1994; 13: 263-72. Anderson JE, Litzow MR, Appelbaum FR et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: The 21-year Seattle experience. J Clin Oncol 1993; 11: 2342-50. Bierman PJ, Anderson JR, Freeman MB et al. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy. Ann Oncol 1996; 7: 151-6. Nademanee A, Sniecinski I, Schmidt GM et al. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodglrin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobihzed peripheral-blood stem cells. J Clin Oncol 1994; 12: 2176-86. Brice P, Divine M, Marolleau JP et al. Comparison of autografting using mobilized peripheral blood stem cells with and without granulocyte colony-stimulating factor in malignant lymphomas. Bone Marrow Transplant 1994; 14: 51-5. Gianni AM, Siena S, Bregni M et al. Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haematopoietic autologous transplantation in poor prognosis Hodgkin's disease. Ann Oncol 1991; 2: 645-53. Sureda A, Brunet S, Lopez JJ et al. High-dose chemotherapy with bone marrow rescue for treatment of Hodgkin's disease. Leuk Lymph 1992; 7 Suppl ; : 29-31. Seymour LK, Dansey RD, Bezwoda WR. Single high-dose etoposide and melphalan with non-cryopreserved autologous marrow rescue as primary therapy for relapsed, refractory and poorprognosis Hodgkin's disease. Br J Cancer 1994; 70: 526-30. Chopra R, Wotherspoon AC, Blair S et al. Detection and significance of bone marrow infiltration at the time of autologous bone marrow transplantation in Hodgkin's disease. Br J Haematol 1994; 87: 647-9. Grimwade DJ, Chopra R, King A et al. Detection and significance of pulmonary Hodgkin's disease at autologous bone marrow transplantation. Bone Marrow Transplant 1994; 13: 173-9. Stewart D, Bierman P, Anderson J et al. High dose chemotherapy hdc ; with autologous hematopoietic rescue in patients age 60 and over. Proc Annu Meet Soc Clin Oncol 1994; 13: Abstr #1260.
Fig. 1 -- Weight gain of Oreochromis niloticus in four experimental courses of treatment: 1 low initial variability size and low density; 2 high initial variability size and low density; 3 low initial variability size and high density; and 4 high initial variability and high density. Low variability: CV 0.0 0.0 and high variability: CV 58.2 2.8. Low density 1 fish 2 L of water and high density 1 fish 0.5 L of water and mercaptopurine.
Melphalan alcohol
Had no effect on response rates to control ILP, caused tumors to regress by 82% and delayed regrowth by 51 days in the setting of melphalan ILP. Although our results with this dose of systemic MIBG are somewhat confounded by the addition of regional MIBG to the perfusate, this empirically derived protocol demonstrates that systemic and regional MIBG can be combined successfully without significant systemic or regional toxicity. The precise dose-response relationship of regionally delivered MIBG to the efficacy of melphalan ILP is an important subject for further research when considering the possible clinical application of this therapy, because ILP in patients lasts for 60 to 90 minutes. This period could potentially allow MIBG to be delivered exclusively as a regional agent. Because melphalan itself is an acid with an equilibrium constant of approximately 2.5, increased activity of the drug is expected in acidic conditions. This has been demonstrated in vitro, 29, 30 and our data show that selective tumor acidification with MIBG and hyperglycemia is an effective technique for increasing the activity of melphalan in vivo as well. Given that ILP permits the delivery of high-dose melphalan to its target tissue, acidification strategies may be well suited to increasing its activity if concerns regarding potential toxicity can be answered. Moreover, although questions regarding the relative contribution of regional versus systemic MIBG in augmenting the effect of melphalan require further study, our data demonstrate that intermediate-dose systemic MIBG can be combined successfully with regional MIBG in a rodent model of ILP to enhance the therapeutic effect of melphalan without prohibitive toxicity. In summary, systemic MIBG and hyperglycemia seem to improve tumor response rates after ILP in a rodent model of human melanoma. Selective tumor acidification with MIBG and hyperglycemia may augment response rates to current regional perfusion in patients without increasing regional toxicity. ACKNOWLEDGMENTS The acknowledgments are available online in the fulltext version at annalssurgicaloncology . They are not available in the PDF version. REFERENCES.
Investigations Toxicities Before cycle 1: FBC, creatinine, LFTs Before other cycles: FBC, creatinine, LFTs Common: mild-moderate nausea, myelosuppression, fatigue, dyspepsia Uncommon: increased glucose, stomatitis, rash, alopecia Rare: interstitial pneumonitis, pulmonary fibrosis, hepatic disorders Delay treatment: Neut 1x109 l & platelets 75x109 l. Delays of 1-2 weeks are acceptable but delays beyond 2 weeks on more than one occasion would be an indication to give G-CSF lenograstin 105mcg on 2-3 days is suggested. Renal impairment: reduce melphalan to 5mg m if serum creatinine is 200micromol l. Glucose levels in diabetic patients. Pregnancy and lactation and meropenem.
Een ILP met histamine in combinatie met verschillende chemotherapeutica resulteert in een synergistisch antitumor effect zonder ernstige lokale of systemische toxiciteit. Histamine heeft vasoactieve eigenschappen, werkt op de tumor-geassocieerde vasculatuur, veroorzaakt verhoogde opname van de chemotherapeutica in de tumor en vernietiging van de tumor vasculatuur. Ook in de IHP wordt een synergistisch antitumor effect van histamine in combinatie met melphalan waargenomen ILP met IL-2 in combinatie met melphalan resulteert in een synergistisch antitumor effect. Het achterliggende mechanisme is gebaseerd op de verhoogde opname van melphalan in de tumor zonder duidelijke schade aan de tumor vasculatuur. Macrofagen spelen een grote rol in een ILP met IL-2 De combinatie histamine-IL-2-melphalan leidt tot een verminderde tumor respons and melphalan.
|
